The global demand for Myasthenia Gravis Disease Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Myasthenia gravis disease can affect people of any age; however, it is more frequent in women under 40 and males over 60. Rapid weariness and weakness of any muscles under a person's voluntary control are symptoms of myasthenia gravis disease. A normal communication breakdown between muscles and neurons causes myasthenia gravis illness. Although there is no exact cure for the MG condition, effective and early therapy can help to reduce symptoms such as double vision, difficulty speaking, eating, swallowing, breathing, arm or muscular leg weakness, and eyelid drooping.
Market Dynamics
The desire to prevent the worsening quality of life due to myasthenia gravis disease drives the global Myasthenia Gravis Disease market. Growing R&D initiatives for innovative medicines are also fueling market expansion. In addition, significant players are involved in cutting-edge research to bring affordable treatments to the market for this condition. However, the lack of familiarity with early symptoms and indicators and the high cost of therapy stifle the market's growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of myasthenia gravis disease. The growth and trends of myasthenia gravis disease industry provide a holistic approach to this study.
Market Segmentation
This section of the myasthenia gravis disease market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Imaging
- Blood Tests
- Electrodiagnostic
- Edrophonium Test
- Pulmonary Function Test
By Application
- Hospitals
- Clinics
- Academic Research Institutes
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Myasthenia Gravis Disease market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Myasthenia Gravis Disease Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the myasthenia gravis disease market include Valeant Pharmaceuticals, Sun Pharmaceuticals Industries, Novartis Pharmaceuticals, Teva Pharmaceutical Industries, Cipla, Roche, Apotex Corporation, Pfizer, Bristol-Myers And Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
METHODOLOGY:
This market research report has been produced by gathering information based on primary and secondary research. Secondary research has been done using various sources, including (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications. Additionally, our team conducts extensive primary research with key industry participants to gather first-hand data. The data is then analyzed and validated by industry experts.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
Frequently Asked Questions (FAQs) about this Report
b. In 2021, the global market size for Myasthenia Gravis Disease was worth USD 1.46 Billion.
b. Between 2023 and 2028, the worldwide Myasthenia Gravis Disease market growth is projected to be nearly 11.5%.
b. North America accounts for the largest market share of the global Myasthenia Gravis Disease market.
b. The Global Myasthenia Gravis Disease is segmented by Type, Imaging, Blood Tests, Electrodiagnostic, Edrophonium Test, Pulmonary Function Test, by Application, Hospitals, Clinics, Academic Research Institutes.
b. The leading players in the Global Myasthenia Gravis Disease Market are Valeant Pharmaceuticals, Sun Pharmaceuticals Industries, Novartis Pharmaceuticals, Teva Pharmaceutical Industries, Cipla, Roche, Apotex Corporation, Pfizer, Bristol-Myers And Company.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . MYASTHENIA GRAVIS DISEASE – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Type
3.7.2 Market Attractiveness Analysis By Application
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL MYASTHENIA GRAVIS DISEASE MARKET ANALYSIS BY TYPE
6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Imaging Historic and Forecast Sales by Regions
6.5 Blood Tests Historic and Forecast Sales by Regions
6.6 Electrodiagnostic Historic and Forecast Sales by Regions
6.7 Edrophonium Test Historic and Forecast Sales by Regions
6.8 Pulmonary Function Test Historic and Forecast Sales by Regions
7 . GLOBAL MYASTHENIA GRAVIS DISEASE MARKET ANALYSIS BY APPLICATION
7.1 Overview by Application
7.2 Historical and Forecast Data
7.3 Analysis by Application
7.4 Hospitals Historic and Forecast Sales by Regions
7.5 Clinics Historic and Forecast Sales by Regions
7.6 Academic Research Institutes Historic and Forecast Sales by Regions
8 . GLOBAL MYASTHENIA GRAVIS DISEASE MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
8.3.1. Overview, Historic and Forecast Sales Analysis
8.3.2. North America By Segment Sales Analysis
8.3.3. North America By Country Sales Analysis
8.3.4. United State Sales Analysis
8.3.5. Canada Sales Analysis
8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
8.4.1. Overview, Historic and Forecast Sales Analysis
8.4.2. Europe by Segment Sales Analysis
8.4.3. Europe by Country Sales Analysis
8.4.4. United Kingdom Sales Analysis
8.4.5. France Sales Analysis
8.4.6. Germany Sales Analysis
8.4.7. Italy Sales Analysis
8.4.8. Russia Sales Analysis
8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
8.5.1. Overview, Historic and Forecast Sales Analysis
8.5.2. Asia Pacific by Segment Sales Analysis
8.5.3. Asia Pacific by Country Sales Analysis
8.5.4. China Sales Analysis
8.5.5. India Sales Analysis
8.5.6. Japan Sales Analysis
8.5.7. South Korea Sales Analysis
8.5.8. Australia Sales Analysis
8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
8.6.1. Overview, Historic and Forecast Sales Analysis
8.6.2. Latin America by Segment Sales Analysis
8.6.3. Latin America by Country Sales Analysis
8.6.4. Brazil Sales Analysis
8.6.5. Argentina Sales Analysis
8.6.6. Peru Sales Analysis
8.6.7. Chile Sales Analysis
8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
8.7.1. Overview, Historic and Forecast Sales Analysis
8.7.2. Middle East & Africa by Segment Sales Analysis
8.7.3. Middle East & Africa by Country Sales Analysis
8.7.4. Saudi Arabia Sales Analysis
8.7.5. UAE Sales Analysis
8.7.6. Israel Sales Analysis
8.7.7. South Africa Sales Analysis
8.7.8. Rest Of Middle East And Africa Sales Analysis
9 . COMPETITIVE LANDSCAPE OF THE MYASTHENIA GRAVIS DISEASE COMPANIES
9.1. Myasthenia Gravis Disease Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10 . COMPANY PROFILES OF MYASTHENIA GRAVIS DISEASE INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Valeant Pharmaceuticals
10.3.1. Company Overview
10.3.2. Company Revenue
10.3.3. Products
10.3.4. Recent Developments
10.4. Sun Pharmaceuticals Industries
10.4.1. Company Overview
10.4.2. Company Revenue
10.4.3. Products
10.4.4. Recent Developments
10.5. Novartis Pharmaceuticals
10.5.1. Company Overview
10.5.2. Company Revenue
10.5.3. Products
10.5.4. Recent Developments
10.6. Teva Pharmaceutical Industries
10.6.1. Company Overview
10.6.2. Company Revenue
10.6.3. Products
10.6.4. Recent Developments
10.7. Cipla
10.7.1. Company Overview
10.7.2. Company Revenue
10.7.3. Products
10.7.4. Recent Developments
10.8. Roche
10.8.1. Company Overview
10.8.2. Company Revenue
10.8.3. Products
10.8.4. Recent Developments
10.9. Apotex Corporation
10.9.1. Company Overview
10.9.2. Company Revenue
10.9.3. Products
10.9.4. Recent Developments
10.10. Pfizer
10.10.1. Company Overview
10.10.2. Company Revenue
10.10.3. Products
10.10.4. Recent Developments
10.11. Bristol-Myers And Company
10.11.1. Company Overview
10.11.2. Company Revenue
10.11.3. Products
10.11.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Type (USD MN)
- Imaging Market Sales by Geography (USD MN)
- Blood Tests Market Sales by Geography (USD MN)
- Electrodiagnostic Market Sales by Geography (USD MN)
- Edrophonium Test Market Sales by Geography (USD MN)
- Pulmonary Function Test Market Sales by Geography (USD MN)
- Analysis Market by Application (USD MN)
- Hospitals Market Sales by Geography (USD MN)
- Clinics Market Sales by Geography (USD MN)
- Academic Research Institutes Market Sales by Geography (USD MN)
- Global Myasthenia Gravis Disease Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Myasthenia Gravis Disease Report
- Market Research Process
- Market Research Methodology
- Global Myasthenia Gravis Disease Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Type
- Market Attractiveness Analysis by Application
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Type (USD MN)
- Imaging Market Sales by Geography (USD MN)
- Blood Tests Market Sales by Geography (USD MN)
- Electrodiagnostic Market Sales by Geography (USD MN)
- Edrophonium Test Market Sales by Geography (USD MN)
- Pulmonary Function Test Market Sales by Geography (USD MN)
- Global Market Analysis by Application (USD MN)
- Hospitals Market Sales by Geography (USD MN)
- Clinics Market Sales by Geography (USD MN)
- Academic Research Institutes Market Sales by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Top Companies Market Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.